A Prospective, Multicenter, Non-Blinded, Non-Randomized Pivotal Study of the Fenestrated TREO Stent-Graft System in Subjects With Abdominal Aortic Aneurysms Requiring a Fenestrated Graft and Suitable for Endovascular Repair

The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System works to treat abdominal aneurysms in adults. An abdominal aneurysm is a bulge in the main blood vessel (the aorta) which carries blood from the heart, through the chest and abdomen. It will also learn about the safety of Fenestrated TREO Stent-Graft System.
The main question it aims to answer is: Can the the Fenestrated TREO Stent-Graft System be used to treat participants with a specific type of abdominal aneurysm called a juxtarenal abdominal aortic aneurysm?
Participants will: Have the the Fenestrated TREO Stent-Graft System implanted via an endovascular surgical procedure and visit the hospital for a follow up period of 5 years, for checkups, tests and imaging scans.

Start Date29 Sep 2025

Sponsor / Collaborator

Bolton Medical, Inc.

NCT07078383

/ Not yet recruitingNot Applicable

Evaluation of the Rapidlink Device for Use in the Repair or Replacement of the Supra-Aortic Vessels During an Open Surgical Procedure of the Thoracic Aorta

The Goal of this Clinical Study is to evaluate the safety and effectiveness of the Rapidlink device in the repair or replacement of the supra-aortic vessels during open surgical repair of aortic disease affecting the thoracic aorta.
This study will collect information on patients who are already having surgery to repair their aorta and who will have Rapidlink device implanted into one or more of the aortic arch vessels.
The first 32 subjects enrolled will undergo left subclavian artery repair or replacement, only, with the Rapidlink device. After the 32nd subject, enrollment will proceed to include subjects undergoing any supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and/or innominate artery) repair or replacement with the Rapidlink device in a planned surgery.
After the 32nd subject is enrolled in the main group, up to 30 subjects will undergo supra-aortic vessel (i.e., left subclavian artery, left common carotid artery, and/or innominate artery) repair or replacement with the Rapidlink device in an emergency setting.
Data will be collected before, during and after surgery including recovery at discharge, 30 days, 6 months, 1 and 2 years after the surgery.

Start Date01 Sep 2025

Sponsor / Collaborator

Vascutek Ltd.

CTRI/2025/06/089051

/ Not yet recruitingNot Applicable

Establishing the efficacy of masking the clinically significant blood group antigens on human RBCs by a biocompatible material - NIL

Start Date01 Jul 2025

Sponsor / Collaborator

Terumo Penpol Pvt Ltd.

100 Clinical Results associated with Terumo Corp.

0 Patents (Medical) associated with Terumo Corp.

301

Literatures (Medical) associated with Terumo Corp.

01 Aug 2025·CYTOTHERAPY

A 3-in-1 integrated automated platform for rapid CAR-T cell manufacturing: activation, transduction, and expansion in a hollow-fiber system

Article

Author: Zhang, Shan ; Huang, Shengchieh ; Zhou, Lijuan ; Wang, Qian ; Yan, Zewen ; Niu, Chunmei ; Leong, Wenyan ; Tan, Louise ; Carroll, Kristina ; Wang, Xuewei

BACKGROUND AIMS:

Modifying a patient's own immune system to treat oncologic and autoimmune diseases using CAR-T therapy has become a major focus of research and clinical studies. While these therapies have immense capacity to treat and even cure diseases on a large scale, barriers such as complex manufacturing processes and long turnaround time impede widespread access. Traditional CAR-T manufacturing involves manual and open steps of activation and viral transduction before expansion, causing inefficiencies, inconsistencies, and extended timelines. A fast and simplified GMP-compliant manufacturing process for high quality CAR-T cells is needed to support broader access and adoption of these therapies.

METHODS:

This article demonstrates the successful integration of 3 steps (activation, virus transduction, and expansion) into 1 automated and functionally closed Quantum™ Cell Expansion System platform, thereby named 3-in-1. PBMCs from 3 healthy donors were isolated, followed by CD3+ T cell enrichment. A total of 1.2 × 10⁸ CD3+ T cells were seeded into the Quantum system for automated activation, viral transduction, and expansion in serum-free culture conditions. The harvested cells were washed and concentrated using CellSep PRO, with quality and functionality evaluated via flow cytometry and a non-radioactive cytotoxicity assay.

RESULTS:

The Quantum system produced over 1.2 × 10¹⁰ cells (117 ± 14 fold expansion) within 7 to 8 days, with on average 44.9 ± 4.0% viral transduction. The manual flask control was able to reach 100-fold expansion from Day 10 with an average transduction efficiency of 25.6+. The cells harvested from Quantum also demonstrated strong cytotoxic activity against NALM-6 cells and a high proportion of T_SCM cells.

CONCLUSIONS:

By providing a concentrated and stable microenvironment, Quantum 3-in-1 simplifies CAR-T workflow, shortens manufacturing cycles, enhances viral transduction efficiency, and generates clinically optimal cell phenotypes.

01 Jul 2025·Journal of diabetes science and technology

Investigation of the Effect of 70 Potential Interferents on Measurement Results of Two Blood Glucose Monitoring Systems

Article

Author: Jendrike, Nina ; Schauer, Sebastian ; Sugiyama, Takayuki ; Tesar, Martina ; Pleus, Stefan ; Haug, Cornelia ; Sugiura, Mako ; Aoki, Takashi ; Mende, Jochen ; Freckmann, Guido ; Baumstark, Annette

Background::

Reliable blood glucose (BG) measurements are important for people with diabetes to manage their therapy as well as in point-of-care testing (POCT) performed by health care professionals to monitor BG of patients or even to diagnose diabetes. Among other factors, endogenous and exogenous substances present in blood samples can impact the measurement results. To ensure and prove that blood glucose monitoring systems (BGMSs) are robust in terms of potential interferents, manufacturers have to perform extensive evaluations.

Method::

An interference screening test was performed for three reagent system lots of a POCT system and of a BGMS for self-monitoring of BG. A paired-difference approach based on ISO 15197:2013 and CLSI guideline EP07 was used with venous whole blood samples at two different glucose concentrations. Seventy potential interferents expected to be common in people with diabetes were evaluated.

Results::

The interference effects were determined as normalized biases between test samples and corresponding control samples. For 69 of the 70 investigated potential interferents, both systems met the predefined acceptance criteria, with the normalized biases falling within ±10 mg/dL or ±10% at glucose concentrations ≤100 mg/dL or >100 mg/dL, respectively, for each of the three evaluated reagent system lots.

Conclusions::

The BGMS investigated in this study were found to be robust with respect to the 70 evaluated potential interferents. Interference effects were observed only for N-Acetyl-L-cysteine. Extensive evaluations of potential interfering factors can make an important contribution to ensure reliability of BGMS.

01 May 2025·JOURNAL OF CONTROLLED RELEASE

Effective transcatheter intracoronary delivery of mRNA-lipid nanoparticles targeting the heart

Article

Author: Kitamura, Tetsuhisa ; Kawamura, Masashi ; Saito, Shunsuke ; Whitehouse, Julia ; Komukai, Sho ; Fujimura, Lisa ; Handa, Kazuma ; Hirano, Kunio ; Miki, Kenji ; Miyagawa, Shigeru ; Fujishiro, Anri ; Harada, Akima ; Sasai, Masao ; Matsuzaki, Takashi

Messenger RNA (mRNA) has great potential to provide innovative medical solutions in the treatment of heart failure. Although lipid nanoparticles (LNPs) are an established mRNA delivery system, effectively delivering LNPs to the heart remains a significant challenge. Here, we evaluated the efficacy of transcatheter intracoronary (IC) administration compared to intravenous (IV) and intramyocardial (IM) administration in normal and ischemia-reperfusion (I/R) model rabbit hearts using LNPs encapsulating Firefly Luciferase (FLuc) mRNA. In the normal model, IVIS spectrum data showed that FLuc expression was widespread throughout the heart in the IC group and was significantly higher than in the IV group, and comparable to the IM group, where it was highly expressed only at the injection sites. Histological analysis revealed that FLuc-expressing cells were observed in cardiomyocytes, endothelial cells, smooth muscle cells, and fibroblasts. In the I/R model, FLuc expression was also significantly higher in the IC group than the IV group, and comparable to the IM group. Although FLuc expression was strongly observed in the infarct area in all three delivery groups, the IC group demonstrated the most widespread FLuc expression in the remote area. Histological analysis revealed significantly higher FLuc-expressing cells in the remote area in the IC group than in the other groups. IC administration effectively delivered mRNA-LNPs not only to the infarct area (damaged area) but also to the remote area (non-damaged area) in the diseased heart. Moreover, VEGF mRNA-LNP administration via the IC method to I/R model rabbit hearts significantly reduced the infarct area and attenuated the impairment of cardiac function caused by I/R injury compared to the other methods. Considering the invasiveness and clinically limited applications of IM administration, our study suggests that less invasive IC administration is a clinically safe and useful method for mRNA-LNP delivery to a wider range of myocardial tissue in the heart.

249

News (Medical) associated with Terumo Corp.

03 Sep 2025

·www.prnewswire.com

Terumo Neuro Launches Aneurysm Treatment Alliance in EMEA to Advance Physician Collaboration and Aneurysm Care

"Bringing Effective Solutions to Life" Through A Dedicated EMEA Initiative Designed to Simplify Collaboration, Showcase A Comprehensive Hemorrhagic Portfolio, And Empower Physicians to Improve Patient Outcomes MARSEILLE, France, Sept. 3, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced the launch of the Aneurysm Treatment Alliance at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) 17th Annual Congress. The Aneurysm Treatment Alliance is a new EMEA initiative created to strengthen engagement with physicians, streamline collaboration, and highlight Terumo Neuro's differentiated hemorrhagic portfolio for aneurysm treatment. By providing standardized tools and a collaborative platform, the Alliance supports physicians in advancing patient care across the region. The Aneurysm Treatment Alliance will feature: Comprehensive portfolio access – showcasing the WEB™ Device, the LVIS™ EVO™ Stent, the FRED™ X Flow Diverter, Hydrogel Coils, and Bare Platinum Coils as part of Terumo Neuro's leading hemorrhagic treatment solutions. Elevating collaboration - continuing to cultivate purposeful engagement with physicians that extends beyond presentations, emphasizing shared expertise, cross-regional perspectives, and dialogue that drives clinical advancement. Cross-regional learnings – enhancing the exchange of insights and best practices across EMEA to improve quality and consistency of physician engagement. Cross-collaboration opportunities – expanding awareness and education on integrated implantable device solutions for aneurysm therapy. "Our hemorrhagic portfolio leads the way in delivering innovative solutions, grounded in strong clinical outcomes, that empower physicians to confidently treat a wide range of aneurysms," said Sebastien Chabeauti, Vice President and General Manager, EMEA, Terumo Neuro. "The Aneurysm Treatment Alliance brings this commitment to life by providing physicians across EMEA with practical tools and collaborative opportunities to elevate aneurysm treatment. This launch also reflects our laser-focused dedication to physician partnerships, innovation, and improving patient outcomes worldwide." About Terumo Neuro We're in business to create and deliver innovations that redefine what's possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro products are sold in more than seventy countries through a dedicated sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit . About Terumo Corporation Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio—from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products. Media Contact: Christine McCullough Head of Global Communications Terumo Neuro + 1 714 206 9800 [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Acquisition

03 Sep 2025

·www.prnewswire.com

Terumo Neuro Unveils New SOFIA™ Flow 88 Neurovascular Aspiration Catheter Data from EMEA Demonstrating Strong Performance

Real-World EMEA Physician Preference Data1 Demonstrates the SOFIA Flow 88 Aspiration Catheter's Trackability, Navigation, and Overall Performance in Stroke Procedures MARSEILLE, France, Sept. 3, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world EMEA physician preference data for the SOFIA Flow 88 Aspiration Catheter at the 2025 European Society of Minimally Invasive Neurological Therapy (ESMINT) 17th Annual Congress. The data—presented publicly for the first time —demonstrates strong performance compared to other aspiration catheters1 in key performance metrics such as trackability, navigation and overall physician-rated experience. Continue Reading SOFIA™ Flow 88 Neurovascular Aspiration Catheter Data for EMEA Demonstrating Strong Performance Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed: 83% of physicians reported that SOFIA Flow 88 catheter reliably reached the target location—even in anatomically challenging cases, with 76% of procedures in ICA-T or beyond 100% of physicians rated SOFIA Flow 88 catheter " Same" or "Better" than SOFIA Plus 6F for ease of trackability to target vessel location 92% of physicians rated the SOFIA Flow 88 catheter as "Same", "Better" or "Much Better" than alternative aspiration catheters overall "The SOFIA Flow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA," said Carsten Schroeder, President and CEO of Terumo Neuro. "Its super bore design maximizes aspiration and minimizes flow disruption while delivering exceptional support. It enables physicians to navigate even the most tortuous anatomies in an atraumatic fashion. We're proud that physician preference data so clearly underlines SOFIA Flow 88 catheter's strong performance. It reinforces the SOFIA catheter family's reputation as 'best in class' for trackability, navigation and overall performance." The SOFIA Flow 88 Neurovascular Aspiration Catheter was commercially launched in the EMEA on June 2, 2025, as the latest addition to Terumo Neuro's global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA Flow 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies. The physician preference data unveiled at ESMINT builds on results from the U.S.-based SOFAST data and the European SESAME Study, which demonstrated the safety and efficacy of the SOFIA™ catheter as a frontline approach in mechanical thrombectomy. The SOFIA Flow 88 catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and is part of Terumo Neuro's fully integrated stroke solution, including: ERIC™ Retrieval Device – For thrombus control and procedural versatility BOBBY™ Balloon Guide Catheter – Offering reliable2 flow arrest with next-gen balloon technology WEDGE™ and HEADWAY™ Microcatheters – Designed for navigation support and access efficiency TRAXCESS™ Guidewires – Soft-tip wires built for challenging anatomies About Terumo Neuro We're in business to create and deliver innovations that redefine what's possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit . About Terumo Corporation Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio—from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products. Reference Data on file Boeckh-Behrens, Tobias & Moehlenbruch, Markus. (2024). P116 The new generation BOBBY balloon guide catheter for mechanical thrombectomies: results of the international prospective STRAIT study. Journal of NeuroInterventional Surgery. 16. A97.1-A97. 10.1136/jnis-2024-ESMINT.152. Media Contact: Christine McCullough Global Corporate Communications Terumo Neuro +1 714 206 9800 [email protected] Info - Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionClinical Study

27 Aug 2025

·www.prnewswire.com

Drug-Eluting Stent Market to Hit USD 9.47 Billion by 2030, Says Mordor Intelligence

HYDERABAD, India, Aug. 27, 2025 /PRNewswire/ -- According to Mordor Intelligence, the global drug-eluting stent market is poised to grow from USD 6.35 billion in 2025 to nearly USD 9.47 billion by 2030, reflecting a healthy 8.3% CAGR. Growth is being fueled by rising demand for minimally invasive cardiac procedures, next-generation designs that reduce the risk of restenosis, and an aging population with more complex healthcare needs. At the same time, broader reimbursement access in emerging economies and evolving hospital purchasing strategies are reshaping the drug-eluting stent market, creating stronger competition and driving innovation at both the product and service level. Key Insights and Trends Shaping the Drug-Eluting Stent Market The global drug-eluting stent (DES) market is undergoing a period of transformation, with several emerging trends influencing growth, competition, and adoption across healthcare systems. From procedure backlogs and technology upgrades to evolving reimbursement policies and demographic shifts, these factors are redefining how hospitals, physicians, and manufacturers engage with this critical segment of cardiac care. Clearing Backlogs Boosts PCI Demand Elective procedure backlogs have driven PCI volumes beyond pre-pandemic levels, prompting hospitals and distributors to adopt more flexible, demand-driven stent planning. Early adopters of radial-access techniques are seeing faster growth in utilization. Next-Gen Stents Gain Ground Stronger safety data and reduced therapy needs are accelerating the shift to second- and third-generation drug-eluting stents. Hospitals are phasing out older models and using tiered inventories to balance cost with complexity. Reimbursement Expands Access Broader reimbursement policies, especially in emerging markets, are enabling wider adoption of advanced stents. Manufacturers are supporting this by pairing regulatory filings with health-economic data to secure faster inclusion in national formularies. Aging Population Shapes Demand Rising elderly populations are driving demand for ultrathin-strut stents and advanced imaging. Hospitals are upgrading technology to manage complex cases, while payers adjust reimbursement to reflect higher-acuity care. Restraints Impacting the Drug-Eluting Stent Market Despite advancements, safety concerns like late-stent thrombosis still challenge the drug-eluting stent market, pushing regulators to demand longer trials and raising costs for smaller firms. Growing adoption of OCT is also shifting preferences toward stents with better visibility. Meanwhile, pricing pressure from group purchasing organizations in mature markets continues to squeeze margins. To counter this, major players are adding value-driven services, while regional manufacturers focus on smaller hospitals and niche markets less affected by price consolidation. Segment Coverage By Coating Polymer-Based Coating Biodegradable Non-biodegradable Polymer-Free Coating By Drug Type Everolimus Zotarolimus Sirolimus Paclitaxel Biolimus Others By Material Cobalt-Chromium Platinum-Chromium Stainless Steel Nickel-Titanium (Nitinol) Others By Stent Generation First Generation Second Generation Third Generation By Deployment Technique Balloon-Expandable Self-Expandable By Application Coronary Artery Disease Peripheral Artery Disease By End-User Hospitals Cardiac Catheterization Labs Ambulatory Surgical Centers Geographic Overview North America Strong reimbursement and early tech adoption keep North America in the lead, with outpatient shifts reshaping buying cycles and new approvals boosting demand. Asia-Pacific The fastest-growing region, where cost-driven local players and global innovators coexist. Mature markets like Japan focus on refinements, while India and Indonesia drive growth through DES adoption. Europe A crowded market shaped by tenders and evidence-led practice. With outcomes showing little variation across coatings, cost and deliverability drive purchasing, pushing makers to innovate in complex cases. Click here for more insights on the Drug-Eluting Stent Market - Drug Eluting Stent Market Key Players Abbott Laboratories Boston Scientific Corporation Medtronic PLC Terumo Corporation Biosensors International Group, Ltd. MicroPort Cook Group Lepu Medical Meril Life Science Cordis Sahajanand Medical Technologies Ltd. Read more about the leading Players in Drug-Eluting Stent Sector: Check out related reports published by Mordor Intelligence: Drug-Eluting Balloons (DEB) Market : Drug-Eluting Balloons (DEB) market is projected to grow from USD 0.79 billion in 2025 to USD 1.19 billion by 2030, reflecting a healthy CAGR of 8.5%. Growth is being fueled by quicker regulatory approvals, clearer reimbursement pathways, and a steady rise in cardiovascular procedures. What was once seen as a niche solution for in-stent restenosis is increasingly becoming a mainstream tool for revascularization. Coronary Stents Market : Coronary Stents Market is expected to grow from USD 8.29 billion in 2025 to around USD 10.43 billion by 2030, reflecting a CAGR of 4.7%. Market expansion is being driven by stable procedure volumes, the transition toward value-based care, and wider use of AI-powered imaging that enhances accuracy while minimizing complications. Hospitals increasingly prefer drug-eluting stents with ultrathin struts that support shorter dual antiplatelet therapy, while procurement reforms in Asia continue to influence global pricing strategies. Peripheral Stents Market: Peripheral Stents Market is projected to rise from USD 5.75 billion in 2025 to USD 8.19 billion by 2030, growing at a CAGR of 7.3%. This momentum is fueled by the increasing prevalence of peripheral artery disease (PAD), steady advances in stent technology, and the wider adoption of minimally invasive procedures that help shorten recovery times. Longer life expectancy, expanding procedure volumes, and the rise of ambulatory surgical centers (ASCs) further support demand . About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For media inquiries or further information, please contact: [email protected] Mordor Intelligence Private Limited Logo: SOURCE Mordor Intelligence Private Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Terumo Corp.

100 Translational Medicine associated with Terumo Corp.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 14 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2

Approved

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Dopamine hydrochloride ( DRDs )	Shock, Cardiogenic More	Approved
Acetaminophen ( COXs )	Pain More	Approved
Autologous skeletal myoblast derived cell sheet (Terumo)	Heart Failure More	Approved
Glucose/Sodium Chloride/L-Sodium Lactate Solution	Electrolyte imbalance More	Approved
Glucose/Sodium Chloride/Magnesium Chloride/Calcium Gluconate Hydrate/L-Sodium Lactate Liquid/Zinc Sulfate Hydrate/Potassium Acetate/Potassium Chloride/Monobasic Potassium Phosphate	Water-Electrolyte Imbalance More	Approved

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis